Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

Kailera Therapeutics presented new Phase 1 data on ribupatide injection flexibility at the EASD 2026 Annual Meeting. Additional oral presentations from Hengrui Pharma also contributed to the clinical evidence for Kailera's pipeline.